Bristol-Myers Squibb Company

Under an acute downside scenario, consolidated revenue declines past the guided $1.5B to $2.0B European Eliquis step down in FY2027 toward consensus low of $45.89B. With $45.05B in total debt, $23.42B in current liabilities, and a pre-tax cost of debt of 5.93%, refinancing $8.84B in upcoming five-year debt maturities amidst contracting operating cash flow reduces free cash conversion well below FY2025's $12,845M. In parallel, clinical development delays, such as the slower event recruitment observed in Cobenfy ADEPT-1, prevent new product commercialization from offsetting loss of exclusivity on Revlimid, Eliquis, and Opdivo, driving terminal valuation multiples down to 8.0x and reducing fair value toward the downside anchor of $27.99.

Narrow

Bristol-Myers Squibb possesses a narrow economic moat grounded in patented drug formulations, regulatory marketing exclusivities, and high switching costs across oncology and specialty biopharmaceutical care. In FY2025, the company delivered $13,724M in operating income on $48,194M of revenue, generating returns on invested capital of 16.02% that exceed its moderate cost of equity of 7.43% and WACC of 6.80%.

However, this moat is inherently time-limited and narrowing due to the finite statutory duration of pharmaceutical patents. Core blockbuster therapies that have anchored the company's financial profile—notably Revlimid, Eliquis, and Opdivo—are entering their loss-of-exclusivity windows. Eliquis faces patent expiry in Europe in mid-Q4 2026 with an anticipated $1.5B to $2.0B revenue step down in FY2027, while Opdivo approaches loss of exclusivity later in the decade. The speed at which generic alternatives erode branded volume once patent protection expires prevents the assignment of a wide economic moat rating.

To defend its competitive position, management is advancing a commercial growth portfolio including Camzyos, Sotyktu, and Reblozyl, while targeting more than 10 new medicine introductions by 2030 and over 30 life cycle opportunities. While early commercial traction is evidenced by Qvantig annualizing over $1B, the multi-year lag between clinical development and commercial scale leaves economic profits exposed to compression over the next five years, justifying a 5-year stage I and 5-year stage II competitive fade structure.

Bristol-Myers Squibb Company (BMY) trades at 9.4x forward earnings against a peer median of 14.6x. Its EV/EBITDA of 8.4x compares with a peer median of 13.2x. The comparison uses 4 peers: Pfizer Inc., Amgen Inc., Merck & Co. Inc. and Biogen Inc., as of 2026-09-25.

We recommend selling or avoiding Bristol-Myers Squibb as the share price of USD 61.94 on September 25, 2026 significantly exceeds our Fair value of USD 42.47. Impending generic erosion on blockbuster therapies Eliquis and Opdivo will drive top-line revenue and net earnings contraction through FY2030.^1,4,5

While management is advancing commercial therapies like Camzyos, Sotyktu, and Reblozyl alongside a late-stage pipeline targeting over 10 new medicine launches by 2030, these assets cannot scale fast enough to bridge the patent cliff, leaving the stock vulnerable to multiple contraction and balance sheet debt refinancing pressures.